Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRX-102 in Children and Adolescents with Fabry Disease
NCT06328608Phase 3Recruiting
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Jul 2025
- Primary completion
- Oct 2028
- Modality
- PEGylated Peptides, Replacement Enzymes
- Countries
- 6
01
Overview
Phase 3, open-label, single-arm trial of pegunigalsidase alfa in Fabry disease (FD), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoints: Incidence of Treatment Emergent Adverse Events at 12 Months, Incidence of Infusion Related Reactions at 12 Months and 22 more. Started Jul 2025; status: recruiting.
02
Drugs
pegunigalsidase alfa
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NCT06328608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06328608.